In brief
The FDA has issued over 100 letters to telehealth companies, including Hims & Hers, marking an effort to tackle misleading advertisements concerning prescription medications, particularly weight loss drugs. This initiative aligns with efforts from the Trump administration aiming for transparency in drug marketing, ensuring ads convey truthful information about risks and benefits. The agency's cease-and-desist approach targets online platforms that have historically sidestepped traditional drug advertising regulations.
In a landmark effort, federal health officials are taking decisive action against telehealth companies promoting versions of prescription drugs without official FDA approval. This action is part of a broader initiative to control pharmaceutical advertising as outlined by the Trump administration.
On Tuesday, the Food and Drug Administration (FDA) publicly posted more than 100 warning letters directed at various online health platforms, including the multimillion-dollar business Hims & Hers, which has gained popularity for offering cheaper alternatives to widely-used obesity medications.
Among the major grievances, the FDA cautioned that Hims claimed its customized drug formulations contained the ‘same active ingredients’ as FDA-approved medications such as Wegovy and Ozempic. The FDA clarified that these alternative formulations from specialty compounding pharmacies lack its review and oversight.
Your claims imply that your products are the same as an FDA-approved product when they are not, emphasized the warning letter dated September 9.
This marks the first time the FDA has actively regulated online drug marketing platforms, which have continuously argued they are exempt from traditional drug advertising laws.
The agency's letters emphasize the need for clarity and truthfulness in pharmaceutical advertising, as stated in a presidential memo that has prioritized consumer protection from misleading health information.
Each warning includes ‘cease-and-desist’ language, taking a notably firm stance unlike the usual bureaucratic tone of past communications. This comes amid ongoing scrutiny of the Hims advertising strategy, which has been criticized for downplaying medication risks while promoting supposed benefits.
The FDA has recognized that increasing demand for obesity medications has led such companies to market their own versions of these drugs. They assert that compounding prescriptions can be justified under FDA exceptions if a drug is customized for individual patient needs.
As the FDA takes this pivotal stance, the potential repercussions for telehealth companies and the broader pharmaceutical advertising landscape could be significant, reflecting a shift toward greater regulatory control in a rapidly evolving digital health space.
